Status:
COMPLETED
Effect of Food on Bioavailability of Modified Release Formulations of Imatinib
Lead Sponsor:
Novartis
Conditions:
Healthy
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
This study will evaluate the effect of food on the relative bioavailability of a single dose of imatinib given as a 800 mg modified release tablet, compared to twice-daily doses of 400 mg film-coated ...
Eligibility Criteria
Inclusion
- Inclusion criteria
- Healthy male or female subjects (postmenopausal women), 18-65 years of age
- Able to communicate well with the investigator and comply with the requirements of the study.
- Exclusion criteria
- Smokers within 3 months
- Subjects using any prescription drug or over-the-counter (OTC) medication (including herbal and alternative medication) within 3 weeks prior to dosing.
- Participation in any clinical investigation within 4 weeks prior to dosing or longer if required by local regulation.
- A past medical history or presence of clinically significant ECG abnormalities
- History of acute or chronic bronchospastic disease (including asthma and chronic obstructive pulmonary disease, treated or not treated).
- History of medications pre-disposing the subjects for GI bleedings/cerebral hemorrhage.
- Women taking any biphosphonates (Fosomax like drugs)
- History of being immunocompromised, including a positive HIV test result.
- A positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result.
- Females nursing infants. Other protocol-defined inclusion/exclusion criteria may apply.
Exclusion
Key Trial Info
Start Date :
September 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2006
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT00420043
Start Date
September 1 2006
End Date
November 1 2006
Last Update
April 5 2016
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.